Literature DB >> 21382954

Qingyihuaji formula inhibits progress of liver metastases from advanced pancreatic cancer xenograft by targeting to decrease expression of Cyr61 and VEGF.

Jian-Hua Yin1, Wei-Dong Shi, Xiao-Yan Zhu, Zhen Chen, Lu-Ming Liu.   

Abstract

OBJECTIVE: To observe the effects of Qingyihuaji formula (QYHJ) on the progression of liver metastases from human pancreatic cancer and to detect the expression changes of some biological factors associated with angiogenesis and metastasis during the development of advanced pancreatic cancer.
METHODS: Nude mice were inoculated intrasplenically with human pancreatic cancer cell line SW1990 and then randomly assigned into 4 groups: a control group and groups QYHJ-A, QYHJ-B, and QYHJ-C. Following this, the mice were treated with or without QYHJ formula for 4 weeks and were sacrificed at the end of the sixth week. The changes in body weight were observed, followed by the livers being excised and weighed. Then, both the numbers and the volume of metastatic nodules per liver were evaluated. Subsequently, the expressions of MMPs, VEGF, and Cyr61 in the tissue of liver metastases were detected by reverse transcription polymerase chain reaction, immunohistochemistry, or Western blot. Finally, the correlation was evaluated between the expressions of the factors associated with metastasis and the growth of liver metastasis.
RESULTS: Liver metastases were identified in 11 of 15 mice (73%) in the control group, 9 of 15 mice (60%) in group QYHJ-A, 6 of 14 mice (43%) in group QYHJ-B, and 8 of 14 mice (57%) in group QYHJ-C both the number and the volume of metastatic nodules per liver same as the ratio of liver-body weight in QYHJ groups were significantly less than the controlled group (P < 0.05). The expressions of Cyr61, MMP-2, and VEGF at the levels of mRNA and protein were decreased in the QYHJ groups when compared with the control, as confirmed by immunohistochemistry detection (P < .05). However, no significant difference was observed in the mRNA expression of MMP-1 and MMP-9 between the QYHJ groups and the control group (P > .05). Regression analysis indicated that QYHJ possessed an evident inhibition against the progression of liver metastasis by downregulating the expression of VEGF and Cyr61 rather than MMP-2.
CONCLUSIONS: The QYHJ formula exerted an inhibitory effect on the growth of liver metastasis from pancreatic cancer, perhaps by targeting VEGF and Cyr61 to some extent.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21382954     DOI: 10.1177/1534735411400315

Source DB:  PubMed          Journal:  Integr Cancer Ther        ISSN: 1534-7354            Impact factor:   3.279


  14 in total

1.  Babaodan Capsule () combined with Qingyi Huaji Formula () in advanced pancreatic cancer-a feasibility study.

Authors:  Li-Bin Song; Song Gao; Ai-Qin Zhang; Xiang Qian; Lu-Ming Liu
Journal:  Chin J Integr Med       Date:  2017-05-27       Impact factor: 1.978

2.  Cyr61 promotes growth of pancreatic carcinoma via nuclear exclusion of p27.

Authors:  Weidong Shi; Jianhua Yin; Zhen Chen; Hao Chen; Luming Liu; Zhiqiang Meng
Journal:  Tumour Biol       Date:  2014-08-08

Review 3.  Targeting tumor-associated macrophages by anti-tumor Chinese materia medica.

Authors:  Wei-Ling Pu; Li-Kang Sun; Xiu-Mei Gao; Curzio Rüegg; Muriel Cuendet; Micheal O Hottiger; Kun Zhou; Lin Miao; Yun-Sha Zhang; Margaret Gebauer
Journal:  Chin J Integr Med       Date:  2017-10-08       Impact factor: 1.978

4.  Antitumor activity of emodin against pancreatic cancer depends on its dual role: promotion of apoptosis and suppression of angiogenesis.

Authors:  Sheng-Zhang Lin; Wei-Tian Wei; Hui Chen; Kang-Jie Chen; Hong-Fei Tong; Zhao-Hong Wang; Zhong-Lin Ni; Hai-Bin Liu; Hong-Chun Guo; Dian-Lei Liu
Journal:  PLoS One       Date:  2012-08-02       Impact factor: 3.240

5.  Clinical Distribution and Molecular Basis of Traditional Chinese Medicine ZHENG in Cancer.

Authors:  Zhen Chen; Peng Wang
Journal:  Evid Based Complement Alternat Med       Date:  2012-07-04       Impact factor: 2.629

6.  Survival Benefits of Western and Traditional Chinese Medicine Treatment for Patients With Pancreatic Cancer.

Authors:  Xue Yang; Jian Hao; Cui-Hong Zhu; Yang-Yang Niu; Xiu-Li Ding; Chang Liu; Xiong-Zhi Wu
Journal:  Medicine (Baltimore)       Date:  2015-07       Impact factor: 1.889

Review 7.  Chinese Herbal Medicines as an Adjunctive Therapy for Unresectable Pancreatic Cancer: A Systematic Review and Meta-Analysis.

Authors:  Bin Li; Run Gan; Quanjun Yang; Jinlu Huang; Pengguo Chen; Lili Wan; Cheng Guo
Journal:  Evid Based Complement Alternat Med       Date:  2015-11-23       Impact factor: 2.629

8.  Chinese herbal medicine suppresses invasion-promoting capacity of cancer-associated fibroblasts in pancreatic cancer.

Authors:  Lianyu Chen; Chao Qu; Hao Chen; Litao Xu; Qi Qi; Jianmin Luo; Kun Wang; Zhiqiang Meng; Zhen Chen; Peng Wang; Luming Liu
Journal:  PLoS One       Date:  2014-04-29       Impact factor: 3.240

9.  Nanog Predicts Poor Prognosis in Human Pancreatic Cancer and Is Downregulated by QingyihuaJi Formula in Pancreatic Cancer Stem Cells.

Authors:  Song Gao; Yan Pan; Libin Song; Lei Dong; Lao I Weng; Peng Wang; Yongqiang Hua; Zhen Chen; Luming Liu
Journal:  Evid Based Complement Alternat Med       Date:  2016-10-17       Impact factor: 2.629

10.  Targeting cancer-related inflammation: Chinese herbal medicine inhibits epithelial-to-mesenchymal transition in pancreatic cancer.

Authors:  Juan Zhang; Peng Wang; Huaqiang Ouyang; Jianhua Yin; Aihua Liu; Chunzheng Ma; Luming Liu
Journal:  PLoS One       Date:  2013-07-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.